๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA ยท Real-Time Price ยท USD
8.23
-0.46 (-5.29%)
Nov 18, 2026, 4:00 PM EST - Market closed

Enanta Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Oct - Sep.

Revenue & Profits

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Sep '26 Sep '25 Sep '24 Sep '23 Sep '22
Revenue
636365.3267.6479.286.16
Revenue Growth
-3.56%-3.56%-3.42%-14.61%-8.07%-11.24%
Gross Profit
636365.3267.6479.286.16
Operating Income
-62.38-62.38-85.35-121.69-137.21-123.84
Net Income
-68.25-68.25-81.89-116.05-133.82-121.76
Earnings Per Share
-2.35-2.35-3.84-5.48-6.38-5.91
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Sep '26 Sep '25 Sep '24 Sep '23 Sep '22
Cash & Investments
194.51194.51188.86248.19369.91278.52
Total Debt
177.65177.65201.06226.06222.4426.69
Net Cash (Debt)
16.8616.86-12.1922.13147.47251.83
Net Cash Growth
----85.00%-41.44%-27.13%
Net Cash Per Share
0.580.58-0.571.057.0312.22

Cash Flow & CapEx

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Sep '26 Sep '25 Sep '24 Sep '23 Sep '22
Operating Cash Flow
---19.27-78.76-103.15-84.78
Capital Expenditures
---12.9-17.95-9.06-2.13
Free Cash Flow
---32.17-96.71-112.21-86.91
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Sep '26 Sep '25 Sep '24 Sep '23 Sep '22
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-99.01%-99.01%-130.66%-179.92%-173.23%-143.74%
Pretax Margin
-108.26%-108.26%-127.90%-174.15%-165.39%-141.82%
Profit Margin
-108.33%-108.33%-125.36%-171.58%-168.95%-141.31%
FCF Margin
---49.24%-142.99%-141.67%-100.87%

Valuation

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingNov '26 Sep '26 Sep '25 Sep '24 Sep '23 Sep '22
Forward PE
-6.266.266.266.266.26
PS Ratio
3.816.093.923.252.9712.48